PROTAGONIST THERAPEUTICS INC
Protagonist Therapeutics (PTGX) is a clinical-stage biotechnology company developing peptide-based therapies, principally for gastrointestinal and immune-mediated conditions. With a market capitalisation around $4.67bn, the company’s value is driven by progress across its development pipeline, clinical trial data and any regulatory or partnership milestones. Investors should note Protagonist is not a commercial-stage pharmaceutical group: its prospects depend on successful trials, regulatory approvals and potential collaborations or licensing deals. That creates upside if candidates advance, but also material downside if trials fail or funding needs intensify. Typical risks include clinical and regulatory setbacks, high research and development spending, and share price volatility common to clinical-stage biotechs. This summary is for educational purposes only; it is not financial advice. Consider your risk tolerance and investment horizon and consult a qualified adviser before making decisions.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Protagonist Therapeutics' stock, expecting it to reach a higher price soon.
Financial Health
Protagonist Therapeutics is showing strong revenue and cash flow, indicating a healthy financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring PTGX
The Plasma Profit Pipeline
Biopharmaceutical leader CSL reported a 14% surge in annual profit, fueled by its plasma division's success. This highlights a growing investment opportunity in companies involved in the plasma-derived therapies market and the broader bioprocessing supply chain.
Published: August 19, 2025
Explore BasketNavigating U.S. Drug Price Reforms
The White House is demanding major pharmaceutical companies slash U.S. drug prices, creating significant market volatility and threatening industry profits. This creates a potential opening for companies that offer cost-saving alternatives, such as generic drug makers and healthcare service providers.
Published: August 5, 2025
Explore BasketNew Opportunities in Endometriosis Treatment
This carefully selected group of biopharmaceutical stocks represents companies that could benefit from Organon's recent discontinuation of its endometriosis drug. Our analysts have identified these firms as potential leaders in addressing the significant unmet needs in women's health.
Published: July 3, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Milestones
Clinical data and regulatory updates can rapidly change prospects, offering potential upside — though results are uncertain and setbacks are possible.
Clinical Reach
Programmes target gastrointestinal and immune conditions with substantial patient need, but commercial success depends on approvals and market access.
Innovation and Risk
Peptide-based approaches may offer novel therapies, yet they come with high R&D costs and binary trial outcomes; consider this if you seek higher-risk exposure.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
